| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2124 | 2018 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1826 | 2022 |
| Genome-wide cell-free DNA fragmentation in patients with cancer S Cristiano, A Leal, J Phallen, J Fiksel, V Adleff, DC Bruhm, SØ Jensen, ... Nature 570 (7761), 385-389, 2019 | 1067 | 2019 |
| Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ... Cancer discovery 7 (3), 264-276, 2017 | 906 | 2017 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ... Annals of Oncology 29 (8), 1853-1860, 2018 | 456 | 2018 |
| Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ... Journal of Thoracic Oncology 11 (9), 1493-1502, 2016 | 417 | 2016 |
| Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ... Journal of Thoracic Oncology 13 (12), 1930-1939, 2018 | 395 | 2018 |
| Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ... Nature 596 (7870), 126-132, 2021 | 389 | 2021 |
| Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ... JAMA oncology 6 (12), 1952-1956, 2020 | 378 | 2020 |
| Antagonists of PD-1 and PD-L1 in cancer treatment EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian Seminars in oncology 42 (4), 587-600, 2015 | 340 | 2015 |
| Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ... International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018 | 328 | 2018 |
| Detection and characterization of lung cancer using cell-free DNA fragmentomes D Mathios, JS Johansen, S Cristiano, JE Medina, J Phallen, KR Larsen, ... Nature communications 12 (1), 5060, 2021 | 326 | 2021 |
| Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ... Cancer research 79 (6), 1214-1225, 2019 | 294 | 2019 |
| Epigenetic therapy inhibits metastases by disrupting premetastatic niches Z Lu, J Zou, S Li, MJ Topper, Y Tao, H Zhang, X Jiao, W Xie, X Kong, ... Nature 579 (7798), 284-290, 2020 | 292 | 2020 |
| Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer MJ Bott, SC Yang, BJ Park, PS Adusumilli, VW Rusch, JM Isbell, ... The Journal of thoracic and cardiovascular surgery 158 (1), 269-276, 2019 | 282 | 2019 |
| PD-1 blockade in anaplastic thyroid carcinoma J Capdevila, LJ Wirth, T Ernst, S Ponce Aix, CC Lin, R Ramlau, MO Butler, ... Journal of Clinical Oncology 38 (23), 2620-2627, 2020 | 280 | 2020 |
| A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more … K Rock, O McArdle, P Forde, M Dunne, D Fitzpatrick, B O'Neill, C Faul The British journal of radiology 85 (1017), e729-e733, 2012 | 276 | 2012 |
| Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors G Curigliano, H Gelderblom, N Mach, T Doi, D Tai, PM Forde, ... Clinical Cancer Research 27 (13), 3620-3629, 2021 | 270 | 2021 |
| Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 … B Ricciuti, X Wang, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ... JAMA oncology 8 (8), 1160-1168, 2022 | 231 | 2022 |
| Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation TJ Braaten, JR Brahmer, PM Forde, D Le, EJ Lipson, J Naidoo, ... Annals of the rheumatic diseases 79 (3), 332-338, 2020 | 194 | 2020 |
Jarushka NaidooAssistant Professor of Oncology, Johns Hopkins UniversityDirección de correo verificada de jhmi.edu